ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil

ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development. To instantly join the conference call by phone, use the following link to

KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

DEFA14A - AVANOS MEDICAL, INC. (0001606498) (Filer)

DEF 14A - AVANOS MEDICAL, INC. (0001606498) (Filer)

ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it

ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ

ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil

ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development. To instantly join the conference call by phone, use the following link to

ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally today to achieve its longer-term value creation goals because of Joe's lea

SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)